Related Experiment Videos
Type I receptor tyrosine kinases as targets for therapy in breast cancer
1Hospital General Universitari Vall D'Hebron, Barcelona, Spain. baselga@hg.vhebron.es
Abstract:
Breast carcinomas express high levels of type I tyrosine kinase receptors and their ligands. For these reason therapies directed at these receptors have the potential to be useful anticancer agents. A series of monoclonal antibodies (MAbs)3 directed against the EGF receptor and the closely related erbB2/HER2/neu receptor are currently under evaluation. These MAbs have shown promising preclinical activity and "chimeric" and "humanized" MAbs have been produced in order to obviate the problem of host immune reactions. These antibodies are currently being tested in clinical trials either alone or in combination with chemotherapeutic agents. Clinical activity with anti-HER2/neu MAbs has been documented in patients with advanced breast cancer. In addition, compounds that inhibit receptor tyrosine kinases have shown significant preclinical activity and are potential candidates for clinical testing.
Insights
Targeting tyrosine kinase receptors, like HER2, with monoclonal antibodies (MAbs) shows promise for breast cancer treatment. Clinical trials are evaluating these therapies, including humanized MAbs, for advanced breast cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Breast carcinomas frequently overexpress type I tyrosine kinase receptors and their ligands, indicating potential therapeutic targets.
- Monoclonal antibodies (MAbs) targeting the epidermal growth factor (EGF) receptor and the erbB2/HER2/neu receptor are being investigated for anticancer activity.
Purpose of the Study:
- To evaluate the potential of therapies targeting tyrosine kinase receptors in breast cancer treatment.
- To assess the efficacy and safety of monoclonal antibodies (MAbs) against EGF and HER2/neu receptors in preclinical and clinical settings.
Main Methods:
- Development and evaluation of monoclonal antibodies (MAbs) against EGF and HER2/neu receptors.
- Production of chimeric and humanized MAbs to minimize host immune reactions.
- Clinical trials testing MAbs alone or in combination with chemotherapy for advanced breast cancer.
Main Results:
- Monoclonal antibodies (MAbs) targeting HER2/neu have demonstrated clinical activity in patients with advanced breast cancer.
- Preclinical studies show significant activity for compounds inhibiting receptor tyrosine kinases.
- Chimeric and humanized MAbs have been developed to improve MAb therapy efficacy.
Conclusions:
- Targeting type I tyrosine kinase receptors with monoclonal antibodies represents a promising strategy for breast cancer therapy.
- Further clinical evaluation of anti-HER2/neu MAbs and receptor tyrosine kinase inhibitors is warranted for breast cancer treatment.